Key Highlights
- Akos Czibere, MD, PhD, named Chief Medical Officer of Aktis Oncology.
- Nearly 20 years of experience in drug development for cancer.
- Former Vice President at Pfizer, leading global oncology strategies.
- Dr. Pankaj Bhargava transitions to Scientific Advisory Board.
Source: PR Newswire
Notable Quotes
- “Akos’ broad experience and deep expertise in oncology drug development and regulatory affairs further strengthens our capabilities to deliver on the significant patient impact potential of our first-in-class Nectin-4-targeted miniprotein radioconjugate, as well as the multiple programs to follow.” — Matthew Roden, PhD, President and Chief Executive Officer at Aktis
- “I am honored to be joining the leadership team at Aktis at a pivotal time in the company’s growth. The Aktis team has built an impressive pipeline of alpha-emitting radiopharmaceuticals that have the potential to offer novel treatment options for patients with cancer.” — Dr. Akos Czibere, Chief Medical Officer at Aktis Oncology
SoHC's Take
The appointment of Dr. Akos Czibere as Chief Medical Officer signifies a strategic strengthening of Aktis Oncology’s leadership team. Dr. Czibere’s extensive background in oncology drug development and regulatory affairs, particularly his success in global registration of innovative therapies, positions Aktis well to advance its pipeline of alpha radiopharmaceuticals. His prior roles at Pfizer and Merrimack Pharmaceuticals highlight his capability to lead and deliver groundbreaking cancer treatments. Dr. Pankaj Bhargava’s transition to the Scientific Advisory Board ensures continued valuable input, maintaining momentum for Aktis’s ambitious goals in oncology therapeutics.
